Myelodysplastic syndromes (MDSs) are a heterogeneous group of malignancies characterized by dysplasia, cytopenia, ineffective hematopoiesis and by an increased risk of transformation to acute myeloid leukemia (AML). This risk is increased from refractory cytopenia with unilineage dysplasia, for example, refractory anemia (RA), with about 2% of cases progressing at 5 years to about 40% in cases with RA with excess blasts (RAEB-2). 1 Cytogenetic abnormalities have prognostic relevance and these have been incorporated into the IPSS score. 2 In contrast, only little is known about molecular aberrations in MDS, especially those associated with progression from MDS to AML. We speculated that in analogy to de novo AML, the etiology of MDS and of AML following MDS can also be viewed as a multistep process with the accumulation of activation mutations of tyrosine kinases (class I mutations) and loss-offunction mutations of hematopoietic transcription factors (class II mutations). 3 To support this hypothesis, we characterized our patient cohort (n ¼ 269) cytogenetically by means of chromosome banding analyses accompanied by fluorescence in situ hybridization, and on the molecular level by analyzing gene mutations frequently detected in MDS and/or AML, that is, mutations of RUNX1, FLT3, MLL, NRAS and NPM1. Fresh blood or bone marrows were obtained between August 2005 and October 2008 from a total of 269 unselected patients after informed written consent was obtained in accordance with the Declaration of Helsinki. The study was approved by the ethics committee of the Bayerische Landesärztekammer before its initiation. Twenty of these patients were analyzed at diagnosis of MDS and later at progression to s-AML following MDS (s-AML), whereas either the MDS sample or the s-AML was available in the residual 249 cases. In total, 188 MDS and 101 s-AML samples were analyzed. Diagnosis was according to standard World Health Organization (WHO) criteria. 4 MDS cases were analyzed at diagnosis except for the samples of 33 cases, which were not available at diagnosis but were analyzed during the course of their disease with a median time from diagnosis to analysis of 15.8 months. The composition of the MDS cohort is given in Table 1 . We included unclassified MDS cases (n ¼ 12) in our cohort only if additional cytogenetic or molecular aberrations could be identified confirming the presence of a neoplastic clone. Even though CMMLs are not classified as MDS according to the new WHO classification, we still included this entity because of the presence of myelodysplastic features, the published high transformation rate to AML (15-30% of cases) and the reported high incidence of RUNX1 mutations (RUNX1 þ ).
A subgroup of 92 MDS patients from our entire MDS cohort were available for the analysis of clinical follow-up data: RAEB-2
Letters to the Editor (n ¼ 31), RAEB-1 (n ¼ 35), RCMD (n ¼ 7), RA/5q-(n ¼ 4), MDS, unclassified (n ¼ 8) and CMML1/2 (n ¼ 7). In this subgroup of 92 patients, the median follow-up was 14.6 months and the median age at diagnosis was 68.2 years (range: 35.7-83.6). Patients in the latter cohort did not receive bone marrow transplantation during their MDS stage. In most cases they received no therapy or supportive care, while single cases received AML-type induction therapy or azacytidine. However, this number is too small to draw any conclusions on a relation between these therapies and the outcome. Therefore, we did not consider therapy as a covariate in the analyses for progression to AML and overall survival.
The molecular characterization of the MDS and s-AML patients is shown in Table 1 , including a subdivision of the MDS samples into subgroups according to the WHO classification. The incidences of NPM1 exon-12 mutations (1.5%, 1/66) and of FLT3-internal tandem duplications (FLT3-ITDs) (0.6%, 1/182) were low at the MDS stage with one incidental case each, consistent with the role of NPM1 mutations as a hallmark of cytogenetically normal de novo AML and of FLT3-ITD as a known progression marker from MDS to AML. Mutations of NRAS in codons 12, 13 or 61 are a well-known event in MDS, whereas MLL-partial tandem duplications (MLL-PTDs) are only poorly characterized. The frequency of 5.7% (10/176) of the NRAS mutations in our MDS cohort is similar to published results and also similar to the frequency (4.4% (8/180)) of MLL-PTDs. Finally, RUNX1 þ represents the most frequent molecular aberration in the MDS cohort with a frequency of 13.8% (26/188), which is similar to the number reported by Chen et al. 5 in primary MDS. To analyze whether these mutations might also have a role in the progression from MDS to s-AML, we compared their frequencies in MDS with the frequencies in s-AML (n ¼ 101) ( Table 1) . NRAS mutations showed only a slight increase from the MDS to the s-AML stage (5.7 and 11.0%, P ¼ 0.178), indicating a role for NRAS mutations as an early event in MDS formation. A trend toward significance was calculated for the contribution of NPM1 mutations as a factor for progression from MDS to s-AML (1.5 and 8.5%, P ¼ 0.082). The low frequency of 8.5% of NPM1 mutations in s-AML following MDS compared with the published 25% NPM1 mutations in unselected de novo AML points to the different disease mechanisms in both entities. However, the low incidence of NPM1 mutations in MDS correlates this mutation with the acute myeloid stage of the disease. In contrast, the incidences of FLT3-ITD, MLL-PTD and RUNX1 þ showed highly significant increases from de novo MDS to s-AML, with the respective values being 0.6-11.9% (Po0.001), 4.4-13.9% (P ¼ 0.009) and 13.8-27.7% (P ¼ 0.007). In agreement with previous reports, the detection of FLT3-ITD in our cohort strictly correlated with the presence of AML, except for one incidental case of advanced-stage CMML, defining this aberration as a cooperating event at the time of progression from MDS to s-AML. 6 Among the MDS entities, RUNX1 þ appeared to have the highest incidence in RAEB-2 (21.7%), which was significantly higher compared with RAEB-1 (5,3%, P ¼ 0.008), but no significant difference was noted between RAEB-2 and s-AML following MDS (27.7%, P ¼ 0.457) ( Table 1 ). Owing to the smaller numbers of cases, the other MDS sub-entities (RCMD, RA/5q-, CMML and MDS unclassified) were excluded from statistical analysis.
The higher frequencies of MLL-PTD and RUNX1 þ in s-AML compared with the MDS stage leave two possible modes of action on how these mutations are involved in progression.
(1) Patients carrying one of these mutations at diagnosis of MDS are more likely to progress or progress faster to AML compared with the residual cases. (2) Mutations are acquired as late events at the MDS stage and induce disease progression to AML together with pre-existing mutations.
Specimens of paired samples from 20 patients were available at diagnosis of MDS and s-AML (Table 2 ). To account for cytogenetic aberrations the paired samples were subdivided into three groups: (1) cytogenetically stable at progression with normal karyotype (NK), (2) cytogenetically stable at progression with aberrant karyotype (AK) and (3) cytogenetically unstable. At diagnosis, 8/20 (40%) paired MDS patients were affected by RUNX1 þ (patients 1, 3, 6, 9, 11, 12, 18 and 20), which could be verified in all cases at progression to AML. In all cases no additional molecular mutation was noted at the MDS stage, except for a coexisting NPM1 mutation in patient 12. At progression to AML 5/8 (62.5%) of these patients acquired additional, cooperating mutations, that is, FLT3-ITD (n ¼ 3) and MLL-PTD (n ¼ 2). Interestingly, another three patients acquired RUNX1 þ at the s-AML following MDS stage (patients 4, 15, 19). The latter finding together with the high incidence of RUNX1 þ in RAEB-2 cases (Table 1) implicates RUNX1 þ as a late event in MDS pathogenesis at least in some of the cases. MLL-PTD appeared in the cohort of paired samples with an incidence of two cases at diagnosis of MDS as the only molecular aberration (patients 4 and 13), and in another three cases MLL-PTD was acquired at progression to AML (patients 9, 10 and 20). With the limitation that the group of paired samples is small (n ¼ 20) and selected only patients whose specimens were available at diagnosis of MDS as well as AML, several conclusions can be drawn for the time of acquisition and for the cooperation of molecular aberrations. RUNX1 þ and MLL-PTD can be early as well as late events, probably precluding them as initiating events in MDS pathogenesis. However, they are Table 1 Characterization of the study cohort according to genetic markers Letters to the Editor mutually exclusive during MDS, which is confirmed in our entire MDS cohort (n ¼ 188) (data not shown). At the AML stage MLL-PTD was associated with RUNX1 þ in 3/5 cases (60%), implicating a cooperating effect between both aberrations, which is somewhat surprising as both mutations are considered as class II mutations. Clinical follow-up data and data on the time from diagnosis of MDS to transformation to AML were available in 92 cases of samples that had been analyzed for RUNX1 (RUNX1 þ : 20/92, 21.7%), MLL-PTD (MLL-PTD þ : 8/92, 8.7%), NRAS (NRAS þ : 6/87, 6.9%) and chromosome banding analyses (NK: 47/92, 51.1% and complex AK: 8/92, 8.7%). In these cases, time to progression to AML and overall survival were analyzed by logrank statistics with respect to RUNX1 and NRAS mutation status, MLL-PTD and karyotype. MDS patients with RUNX1 þ progressed to s-AML with a median of 9 months, whereas the median was not reached in RUNX1À cases (P ¼ 0.004). As RUNX1 þ appeared with the highest incidence in RAEB-2 patients, log-rank statistics were also applied to this MDS subgroup (n ¼ 31). However, we could not find a significant correlation of RUNX1 þ compared with RUNX1À with respect to progression in this small cohort (median ¼ not reached vs 22 months, P ¼ 0.265). In addition, MDS cases with MLL-PTD compared with cases without MLL-PTD, and cases with complex karyotype vs all other karyotypes progressed within the following periods: median ¼ 7.7 months vs not reached (P ¼ 0.028) and median ¼ 3.6 months vs not reached (P ¼ 0.005), respectively. No significant effect of NRAS mutations (medians not reached, P ¼ 0.725) and of NK was noted, with a median time to progression of 24.5 months of cases with NK and of 17.3 months of cases with AK (P ¼ 0.825). In contrast to this analysis, RUNX1 mutation status had no significant impact on the overall survival (medians not reached, P ¼ 0.177). The presence of MLL-PTD and complex karyotype resulted in the following values for overall survival: median ¼ 14.6 months vs not reached (P ¼ 0.031) and 3.7 months vs not reached (Po0.001), respectively (NRAS and NK not shown).
The independent prognostic values of RUNX1 þ , MLL-PTD þ , NRAS mutations, normal and complex karyotype, as well as age at diagnosis and blast count as evaluated by cytomorphology were tested by Cox regression analyses with respect to time to progression and overall survival. Blast count was included as a variable in linear regression analyses to account for the high number of RAEB-1 and RAEB-2 samples in our study. All parameters that were identified in univariate analyses to carry significant prognostic value were further evaluated in multivariate analyses. The results of these analyses are shown in Table 3 . However, no IPSS information was available for our cohort and numbers for lower-risk MDS are too small to enable valid conclusions regarding prognostic relevance. This has to be evaluated in future trials.
In conclusion, our results show that RUNX1 þ mutations are the most frequent molecular alterations in MDS and are even significantly increasing in s-AML following MDS. The acquisition of MLL-PTD or FLT3-ITD in MDS patients with RUNX1 þ appears to be a mechanism for rapid leukemic transformation.
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SS, WK, CH, TH own and are employed by the Munich Leukemia Laboratory (MLL) GmbH. NW, JS, TW and FD are employed by MLL GmbH. Thank you for the letter. It is reminiscent of discussions at the Pediatric Oncology Group meetings in the 1980s. Members engaged in hematopoietic stem cell transplantation for acute leukemia (HSCT) were unable to agree on patient selection and standard regimens of chemotherapy, myeloablation and transplantation; they refused to conduct randomized comparisons. The predictable consequence is that over 20 years later, the American Society of Blood and Bone Marrow Transplantation, the editorial and the letter agree that 'well-designed randomized controlled trials of HSCT versus chemotherapy have not been conducted successfully,' in the letter's words. Without such trials no one can be certain about their relative efficacy and safety, only that HSCT generally requires considerably more procedural risk and investment of human and material medical resources. An irony is that federally sponsored cooperative clinical cancer therapy groups were initiated in the 1950s to conduct conclusive clinical trials of cancer treatments.
The editorial pertained only to allogeneic hematopoietic cell transplantation but to accommodate the letter its term HSCT will be used.
Several statements in the letter need to be clarified. For example, the statement that 'the vast majority of children live happy productive lives, with good health, and normal growth and development' is not substantiated by any data. In this regard, Baker et al. 2 reported recently that hematopoietic transplant survivors are 3.5-fold more likely to develop severe or life threatening conditions than age and gender-matched siblings. Two-thirds had at least one chronic condition and one-sixth a severe or life threatening condition. They also had a 14-fold increased risk of difficulty in holding a job. This confirms earlier reports of long-term consequences of HSCT cited in the editorial.
Another example is the citation of Goldsby et al. 3 regarding late neurological effects of childhood leukemia therapy. The article confirms the role of cranial radiation as in the editorial but does not report analysis for a possible HSCT effect.
A criticism is raised in the letter that the editorial fails to mention late effects of chemotherapy alone. But two references are made, both demonstrating the low incidence of long-term morbidity when preventive radiation became excluded in the 1980s as compared to earlier patient cohorts when it was almost routine. This was particularly true when use of anthracyclines and alkylating agents was minimized and synchronous administration of intravenous and intrathecal methotrexate avoided.
The letter is critical of the UKALL R1 and the Children's Oncology Group (COG) CCG-1952 studies cited in the editorial and suggests that the COG-International Blood and Marrow Transplant Registry (IBMTR) study that is also cited and the acute lymphoblastic leukemia (ALL)-Berlin-Frankfurt-Mü nster (BFM) 90 and 95 study of T-cell ALL that is not mentioned are better examples of HSCT evaluation. The letter is correct that the COG-IBMTR study does report overall survival, but it also states that 'because ours is not a randomized study there are several potential biases that may have affected the outcomes described in this report.' It also fails to describe and compare early and delayed toxicity of chemotherapy alone versus chemotherapy followed by HSCT, a necessary component of evaluation. The same is true for the non-randomized ALL-BFM study of T cell ALL, which also describes biases of 'unknown size and direction' and omits treatment sequelae. 4 Especially disappointing is Table 1 in the letter, citing current COG indications for HSCT. 1 It includes ALL with t(9;22) genotype or hypodiploidy despite COG's recent publications suggesting no advantage of HSCT for these subtypes of ALL.
When treatment of children with acute leukemia changed from palliation to intent to cure in 1962, three goals were set: permanent elimination of leukemia, normal health and capacity for growth, and accessibility to all children in need. Innovative pilot studies of combination chemotherapy followed by sciencebased comparative trials have achieved the first goal in the majority of children. Treatment modifications such as omitting irradiation and restricting use of alkylating agents, anthracyclines and epipodophyllotoxins have addressed the second goal with considerable although not complete success. Accomplishment of the third goal is in progress as childhood cancer centers in more privileged nations work with pediatric services in the less privileged to devise simpler, less costly and more readily accessible treatment suited to their circumstances.
The success of HSCT in eliminating residual leukemia depends on producing an alloimmune state in which the donor immune system controls the leukemia by a graft-versus-leukemia reaction, so far inseparable from a graft-versus-host reaction. This was first demonstrated in experimental mice by Barnes and Loutit 5 and confirmed in humans with T-cell depleted HSCT experiments. This alloimmune state combined with the usual
